Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2015

O-Sullivan IS, Zhang W, Wasserman DH, Liew CW, Liu J, Paik J, et al. Erratum: FoxO1 integrates direct and indirect effects of insulin on hepatic glucose production and glucose utilization. Nat Commun. 2015;6:7861.

Roma AA, Goyal A, Yang B. Differential Expression Patterns of GATA3 in Uterine Mesonephric and Nonmesonephric Lesions. Int J Gynecol Pathol. 2015;34(5):480-6.

Kiuru M, Camp B, Adhami K, Jacob V, Magro C, Wildman H. Treatment of metastatic cutaneous Crohn disease with certolizumab. Dermatol Online J. 2015;21(11).

Tomasetti C, Marchionni L, Nowak MA, Parmigiani G, Vogelstein B. Only three driver gene mutations are required for the development of lung and colorectal cancers. Proc Natl Acad Sci U S A. 2015;112(1):118-23.

Khani F, Epstein JI. Prostate Biopsy Specimens With Gleason 3+3=6 and Intraductal Carcinoma: Radical Prostatectomy Findings and Clinical Outcomes. Am J Surg Pathol. 2015;39(10):1383-9.

Hannah J, Zhou P. Methods: A small-molecule SMASh hit. Nat Chem Biol. 2015;11(9):637-8.

Crescenzo R, Inghirami G. Anaplastic lymphoma kinase inhibitors. Curr Opin Pharmacol. 2015;23:39-44.

Niesvizky R, Badros AZ, Costa LJ, Ely SA, Singhal SB, Stadtmauer EA, et al. Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Leuk Lymphoma. 2015;56(12):3320-8.

Boi M, Gaudio E, Bonetti P, Kwee I, Bernasconi E, Tarantelli C, et al. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. Clin Cancer Res. 2015;21(7):1628-38.

Correction to Supporting Information for Talantova et al., Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci U S A. 2015;112(28):E3751-2.